Codice QR

Personalized ctDNA detection and genomic profiling in the NeoRHEA Study

Abstract Circulating tumor DNA (ctDNA) is a promising biomarker in early hormone receptor (HR) + , HER2-negative breast cancer. We assessed ctDNA with the RaDaR assay in NeoRHEA (NCT03065621), a single-arm, phase II neoadjuvant palbociclib plus endocrine therapy trial over 4 months (4 × 28-day cycle...

Descrizione completa

Salvato in:
Autori principali: Alexandra Stanciu, Elisa Agostinetto, Andreas Papagiannis, Christodoulos Pipinikas, Amber Chevalier, Nathan Campbell, Mariana Brandão, Lieveke Ameye, Marianne Paesmans, Tatiana Besse, Francoise Rothe, Laurence Buisseret, Donatienne Taylor, Patrick Neven, Christos Sotiriou, Francois P. Duhoux, Peter Vuylsteke, Michail Ignatiadis
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Portfolio 2025-12-01
Serie:npj Breast Cancer
Accesso online:https://doi.org/10.1038/s41523-025-00852-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi